| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17285 R72352 |
Madley-Dowd_UK (Topiramate) (Controls exposed to LTG) (Mixed indications), 2024 | Intellectual disability - ICD10 codes - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.98 [0.23;17.02] excluded (control group) |
-/154 -/939 | - | 154 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17270 R72353 |
Madley-Dowd_UK (Topiramate) (Controls unexposed, general pop) (Mixed indications), 2024 | Intellectual disability - ICD10 codes - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 3.12 [0.43;22.82] | -/154 1,119/514,066 | - | 154 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17278 R72354 |
Madley-Dowd_UK (Topiramate) (Controls unexposed, sibling) (Mixed indications), 2024 | Intellectual disability - ICD10 codes - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | sibling excluded | Adjustment: Yes |
1.35 [0.14;12.70] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12715 R53760 |
Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
3.79 [1.56;9.22] C excluded (control group) |
6/471 27/7,950 | 33 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12716 R53761 |
Bjørk (Topiramate) (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
3.92 [1.76;8.74] excluded (control group) |
6/471 16,384/4,463,879 | 16,390 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12718 R53762 |
Bjørk (Topiramate) (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 2.00 [0.88;4.54] C | 6/471 139/21,634 | 145 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10103 R46453 |
Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Diagnosis Mental retardation (F70–F79) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
0.50 [0.10;3.30] excluded (control group) |
2/477 15/2,916 | 17 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8613 R46454 |
Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 | Diagnosis Mental retardation (F70–F79) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.70 [0.40;6.80] | 2/477 3,398/1,710,441 | 3,400 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8615 R46452 |
Rihtman (Topiramate) (Mixed indications), 2012 | General IQ (FSIQ) (Stanford Binet) (mean age around 4 years old) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No extrapolated (cont. endpoint) Matched | 9.72 [1.98;47.82] | -/9 -/18 | - | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 2.65 [1.33;5.28] | 3,545 | 1,111 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (Controls unexposed, general pop) (Mixed indications; 2: Topiramate) (Controls unexposed, sick) (Mixed indications; 3: Topiramate) (Controls unexposed, NOS) (Mixed indications; 4: Topiramate) (Mixed indications;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 10103, 12715, 12716, 17285, 17278